Georg Kunz

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

Tanja Fehm, Carsten Denkert, Peter A Fasching, 2012, The New England journal of medicine.

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

Carsten Denkert, Manfred Dietel, C. Denkert, 2013, PloS one.